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Abstract
Background: Menopause is associated with changes in sexual function which are partly due to vaginal atrophy in
response to estrogen reduction. Estrogen administration temporarily reduces the symptoms of vaginal dryness, but
long-term exposure to this drug is likely to be associated with serious complications. Considering the promising
results of previous studies concerning the effect of vitamin D on vaginal dryness, the proposed study will
investigate the effect of vitamin D vaginal suppository on the sexual function of postmenopausal women.
Methods: In a randomized, controlled clinical trial, 105 postmenopausal women will be randomly assigned to three
groups receiving vitamin D vaginal suppository, placebo vaginal suppository, or control (no intervention). Vitamin D
vaginal suppositories contain 1000 units of vitamin D3. The timing of the use of vitamin D vaginal suppositories and
placebo suppositories will be every night in the first 2 weeks, and every other night in the following 6 weeks (8
weeks in total). The primary outcome will be the sexual function of participants which will be assessed using the
Female Sexual Function Index (FSFI) before and immediately after the intervention, and at 1 and 2 months after the
end of the intervention. The side effects of these suppositories will be examined as a secondary consequence of
the study. Data will be analyzed using SPSS software version 25. In the case of normal distribution of data, the
mean score of sexual function will be compared between the groups using a repeated measurements ANOVA. If
statistical analysis leads to significant results, the post-hoc test will be used to determine the differences between
the groups. Comparison of demographic and fertility characteristics of the women will be carried out using
statistical tests such as chi-squares and t-tests. A significance level of p < .05 will be used for statistical analyses.
Discussion: If vitamin D vaginal suppositories improve sexual function among premenopausal women with long-
term effects and minimum side effects, the suppositories will be considered a safe complementary and alternative
choice for alleviating sexual dysfunction among this group.
Trial registration: IRCT20180704040346N1 at 2018-10-13 prospectively registered.
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Background
Menopause – as one of the critical and inevitable stages
of women’s life – is the most important event during
middle age. It can have a particular influence in women’s
personal, cultural, social, reproductive health, and sexu-
ality [1]. Menopause leads to many physiological changes
that occur continuously and gradually, and can affect the
woman’s life [2]. Menopause occurs gradually from the
late third decade of life between the ages of 40 and 60
years and a mean of 51 years [1]. According to studies
conducted in Iran, the range of menopausal age ranges
between 46 and 52 years [3].
The climacteric phase and menopause are the periods
of reductions in the production of hormones, that can
affect women’s quality of life because of various compli-
cations [4]. These complications can include symptoms
such as hot flushes, night sweats, palpitations, bone loss,
urinary problems, and vaginal dryness [5]. Vaginal dry-
ness (as one of the problems caused by the reduction of
estrogen production) is due to thinning of the endomet-
rial tissue and increase of pH, that cause local itching,
an increase in the incidence of vaginal infection, and va-
ginal structural weakness. In addition, dyspareunia can
cause sexual dysfunction and loss of sexual desire during
menopause [6]. Vaginal atrophy, after hot flushes, is the
second most common complication and is the worst
complication of menopause [4]. Reducing estrogen levels
through causing fractures in collagen and elastin fibers
in the vagina causes vaginal atrophy. From a cytomor-
phological aspect, parabasal cells are increased and inter-
mediate and superficial cells are decreased [7].
Problems with vaginal atrophy are clinically manifested
4–5 years after the beginning of menopause [8]. Vulvovagi-
nal atrophy lead to vaginal dryness, irritation, soreness, and
consequently dyspareunia [9, 10]. Approximately one-third
of postmenopausal women report painful intercourse (dys-
pareunia), lack of moisture, and decreased lubrication [11].
Common symptoms of atrophy include vaginal dryness,
burning, post-coital bleeding, and pain [12]. In clinical
examination, symptoms such as being pale, the reduction
of transverse vaginal folds (roga), petechiae, reduced elasti-
city, and dryness confirms the presence of atrophy [5]. Va-
ginal atrophy is one of the causes of sexual problems, and is
one of the most important complaints among women dur-
ing the menopause, but despite many advances in the pre-
vention and treatment of menopausal complications, sexual
problems are underestimated [13].
One of the therapeutic methods for improving the
symptoms of vaginal atrophy and dyspareunia in post-
menopausal women is estrogen therapy [14]. Estrogen
improves the mucosa, and increases elasticity and blood
flow to vulva and vaginal area. It also increases the sen-
sory threshold of the vulva region and vagina, increases
sexual pleasure, and improves arousal [15]. Since
estrogen deficiency is the main cause of vaginal atrophy,
estrogen therapy after menopause is the most rational
choice of treatment. Systemic estrogen therapy is the
gold standard in slowing down and/or preventing early
genital atrophy, but maintaining its effect requires con-
tinuous treatment [2]. The other initial and preferable
and choice in treating genitourinary syndrome of meno-
pausal women is ultralow-dose topical estriol [16]. Over-
all, due to the potential risks of postmenopausal
systemic hormone replacement therapy, estrogen re-
placement therapy may not be acceptable by many
women [8]. Concerns about the complications of estro-
gen therapy, including cardiovascular events, thrombo-
embolism, breast cancer, and endometrial hyperplasia
are the most important reasons for the low acceptance
of synthetic estrogen therapy [17]. In addition to the
aforementioned concerns, a considerable proportion of
menopausal women experience some type of chronic
disease such as diabetes, cardiovascular disease, dyslipid-
emia, and asthma [18], so they are not good candidates
when administering many kinds of hormone therapy.
Regarding these issues, there is an increasing tendency
to utilize alternative treatments for relieving menopausal
symptoms [17].
Vitamin D is one of the essential substances in meta-
bolic and physiological processes in the body [19]. Recent
literature has reported the role of low level of vitamin D in
many pathological conditions including cardiovascular
disease, type 2 diabetes mellitus, metabolic syndrome, can-
cer, and increased mortality, as well as its role in calcium
and bone metabolism [20]. Recent research has also
shown that vitamin D3 may be useful in preventing vagi-
nal atrophy. Vitamin D3 may play a role in regulating the
growth and differentiation of the vaginal epithelium. Cost-
antino’s research found that taking vitamin D3 can help
prevent osteoporosis and eliminate vaginal discomfort
after the menopause [6]. Vitale et al. (2018) reported after
a randomized, placebo-controlled trial, that oral supple-
ments of vitamin D in combination with isoflavones, cal-
cium, and inulin significantly improved the sexual
function of menopausal women [21]. In a cross-sectional
study, Yildirmal et al. (2004) showed that the use of vita-
min D supplements was effective in the maturation of va-
ginal cells [22]. Also, a clinical trial by Zainlugl et al.
(2007) showed that in postmenopausal women with osteo-
porosis, Raloxifene and vitamin D supplementation signifi-
cantly reduced vaginal dryness and pH [23].
Vitamin D3 can be absorbed in the vagina by applying
a vaginal suppository [11]. The results of a clinical trial
study by Rad et al. (2014) on postmenopausal women in
Ahwaz (Iran) showed that vitamin D suppositories could
experimentally (according to the results of the partici-
pants’ Pap smear) improve dryness and cell proliferation
of the vaginal mucosa among postmenopausal women
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[24]. The possible mechanism for the effect of vitamin D
on the vagina is due to the presence of intracellular re-
ceptors of this vitamin in the basal and parabasal cellular
layer in the vaginal tissue. Because of these receptors in
the vagina, vitamin D can play an important role in
regulating and increasing the proliferation of epithelium
cells in vagina [25, 26]. However, vitamin D receptors
change during the menstrual cycle, which means that by
stopping ovarian activity, the number of receptors are
decreased [27].
The results of experiments in rats have shown that ovar-
ian harvesting results in the loss of vitamin D receptors. It
has been shown that the use of vitamin D in mice increases
the number of vitamin D receptors and the coating tissue
becomes better integrated [25, 28]. The biological effect of
vitamin D is applied via the nucleus receptors. These recep-
tors are found in several tissues such as the liver, kidney,
thyroid, adrenal gland, gastrointestinal tract, breast, and
skin. Together, vitamin D and its receptors can negatively
or positively affect the transcription of genes. Therefore,
vitamin D is effective as a precursor in the differentiation
and amplification of keratinocytes and restoring mucosal
tissue of the vagina [29]. In addition, research has shown
that squamous cell differentiation takes place in several
steps, each of which is controlled by specific genes [30, 31].
The present review of existing literature shows that
there are a few studies on the effect of vitamin D on va-
ginal atrophy and the efficacy of treatment has mostly
been investigated under laboratory conditions using the
Pap smear. No study has investigated the effect of vita-
min D on clinical manifestations such as sexual function
of postmenopausal women. On the other hand, the re-
sults of available studies have not been consistent. For
example, Yildirmal et al. (2004) reported that the symp-
toms of vaginal atrophy in both Vitamin D treatment
and control groups and that there were no significant
differences between the groups [22]. On the other hand,
Rad et al. (2014) reported significant differences after
the end of 8 weeks among an intervention group with
vitamin D vaginal suppository compared to the control
group [24]. In another study, vitamin D was also used in
combination with other treatments such as topical ste-
roids and raloxifene [23], but the study did not provide
conclusive evidence concerning the efficacy of vitamin D
on vaginal atrophy. Other limitations of these studies
were that some of them did not use a control group,
random allocation, and blindness, and the duration of
the follow-up of patients was short. Therefore, since
there is no previous study concerning the clinical effect
of the use vitamin D on women’s sexual function, and
considering the strengths and weaknesses of previous
studies, the proposed study is designed to evaluate the
effect of vitamin D3 vaginal suppositories on the sexual
function of postmenopausal women.
Goals and hypotheses
The present study is based on the hypothesis that vitamin
D vaginal suppository will have an effect on the sexual
function of postmenopausal women by improving the
symptoms of vaginal atrophy. As explained above, the pos-
sible mechanism might be due to the regulating and pro-
liferative function of intracellular receptors of vitamin D
in the basal and parabasal cellular layer in the epithelial
tissue of the vagina [25–27]. The results of experiments in
rats as well as a few approved clinical trials demonstrate
that the use of vitamin D increases the number of vitamin
D receptors and that the coating tissue is better integrated
[24, 25, 28]. With this background in mind, the specific
objectives of the proposed study include the:
 Comparison of sexual function in postmenopausal
women within intervention, placebo, and control
group, before, immediately after, and one and 2
months after the intervention;
 Comparison of sexual function in postmenopausal
women between the intervention, placebo, and
control groups immediately after, and one and 2
months after the intervention.
Methods/ design
Research setting and design
The proposed study is designed as a randomized clinical
trial with two parallel control groups of placebo and no
intervention. Participants will be married women be-
tween the ages of 45 and 65 years referred to compre-
hensive health centers in the city of Buin Zahra, who
meet the inclusion criteria. Buin Zahra is one of the cit-
ies of Qazvin province. This city consists of four areas
(central, Dashtabi, Ramand and Shal). Figure 1 provide
study flowchart.
Participants
All postmenopausal women aged 45- to 65-years-old liv-
ing in Buin Zahra district will be invited to participate in
the study via their health care providers. Eligible partici-
pants from 25 urban and rural comprehensive health
center affiliated to abovementioned four districts of Buin
Zahra will be included in this study. The exclusion cri-
teria will be (i) the presence of other endocrine diseases
such as Cushing disease, diabetes, etc., (ii) using other
vaginal drugs, (iii) having moderate to severe vaginal in-
fection, (iv) undergoing hormone therapy, (v) having a
stressful experience during the past 3 months, (vi) ex-
periencing pelvic abnormalities, (vii) having recent sur-
gery, and (viii) unwillingness to participate in the study.
Also excluded will be those with absolute contraindica-
tions of vitamin D supplement including sarcoidosis,
hyperphosphatemia, hypercalcemia, hyper-vitamin D
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levels, arteriosclerosis, kidney stones, and kidney disease
that causes a reduction in kidney function.
Sample size estimation
According to previous study by Çayan et al. [32], consid-
ering α = 0.05, power = 80%, moderate effect size 0f 0.6,
the sample size for the research study was estimated to
be 25 people for each group. Considering the attritional
loss of 40% of the samples in the research process, the
sample size for each group was calculated to be 35
people. The sample size calculation was performed ac-
cording to primary outcome of study.
Recruitment
To recruit the participants, eligible individuals will be se-
lected on the basis of information in the health records
of the comprehensive health centers in the city of Buin
Zahra. A total of 105 eligible individuals will be invited
to participate in the study. After screening the eligible
individuals based on their health records, they will be
called and invited for a visit in their comprehensive
health care center. When they come for the screening
visit, they will interviewed to assess eligibility criteria,
introducing the project, its’ aim, their autonomy to par-
ticipate in the study, confidentiality and anonymity of
collected data. After signing the written consent, they
will be randomized to study groups.
Randomization
The participants will be randomly assigned into the
study groups. Random allocation will be carried out
using the simple randomization method, and assignment
sequences will be written on paper before the start of
the research as either A (suppository of vitamin D3
Fig. 1 Consort diagram of study
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group), B (placebo suppository group), and C (control
group without intervention). Randomization will be per-
formed using random allocation software. The type of
intervention will be written in accordance with the as-
signment sequence and will be enclosed within the
opaque envelopes. Questionnaires will be also encoded
in sequence. In this case, the questionnaire with the
same code will be completed for the person receiving
the code 1 intervention.
Blinding
Due to having a control group which receives no inter-
vention, blinding cannot be performed for all groups.
But in try to blind intervention and placebo controlled
group, vitamin suppositories and placebo suppositories
will have the same color and shape and will coded as A
and B by a pharmacologist not involved in the research
team. The researchers will receive the suppositories with
codes and will not know what A and B stands for with
respect to the suppositories. Finally, after collecting
questionnaires and analyzing data using SPSS version 25
software, the codes that belong to the groups will be
determined.
Intervention
After selecting the participants and random allocation to
the groups, the participants’ sexual function will be
assessed before the intervention. The participants in the
treatment group will receive the vitamin D3 suppository
and the placebo group will receive placebo suppositories
identical the vitamin D3 suppositories in appearance. No
intervention will be performed in the control group.
The use of vitamin D3 and placebo vaginal suppositor-
ies are consistent with the protocol used in the study by
Rad et al. [24]. For 8 weeks, a single dose of 1000 unit
vitamin D3 will be taken every night for the first 2
weeks, and every other night for the following 6 weeks.
The reason for the choice of dosage and similar thera-
peutic protocol is because of the significant results re-
ported in the improvement of para-clinical symptoms of
vaginal atrophy based on the Pap smear. Since the re-
sults of this treatment have not been evaluated clinically,
a similar dose is chosen for this study to examine the ef-
fect of vaginal vitamin D on sexual function.
Storing vitamin D and placebo suppositories
The basis of the suppository is mono, di, and triglyceride
called AM-15 suppository and synthesized by Gattefosse
France. The base melting point is 34–36 degrees. Sup-
positories will be produced by melting and molding
under the supervision of a pharmacist and will be pro-
duced by pharmaceutical experts from the pharmaceut-
ical laboratory of the Faculty of Pharmacy of Mashhad
University of Medical Sciences, Mashhad, Iran. Each
suppository drug weighs 1 gram and contains 1000 units
of vitamin D3. They have a sufficient mechanical
strength and a smooth, uniform, whitewashed surface.
After producing the suppositories, the correct amount
will put in in tight plastic packages and placed in plastic
containers at a temperature below 25 degrees, preferably
kept in the refrigerator. Placebo suppositories will be
made in exactly in the same way using Suppocire AM-
15, with the exception that they lack the medication.
They will be similar to pharmaceutical suppositories in
terms of shape and color.
Intervention program and patient education
During the first visit, the vaginal suppositories (without
identifying the type of suppository, only having an iden-
tifier code inside the appropriate envelopes) will be given
to the participant. The method and duration of use, as
well as the follow-up time will be taught by the re-
searcher to each participant. A phone number will be
provided to ensure that the supplements are properly
used and participants will reminded to keep track of the
follow-up time. The researcher’s phone number will be
shared with the participants to contact them if they have
any questions about how to use the suppositories and/or
if they experience any problems or signs of burning and
itching following the use of the suppositories. As noted
above, the total time period to take the suppositories for
each postmenopausal woman will be 8 weeks, during
which the investigator will monitor the use of the sup-
positories in the women by telephone or text-messaging
(based on the convenience of the participant).
Teaching the participants on how to use vaginal
suppositories
Participants will be informed that (i) the suppository
should be placed inside vagina before bedtime, but
should not be inserted more than 3 inches inside the va-
gina, (ii) before placing the suppository in the vagina,
their hands should be washed with water and soap, (iii)
every night, only one suppository should be inserted into
vagina, and (iv) the treatment schedule will be every
night for 2 weeks and every other night for 6 weeks.
Primary outcome measurements
Sexual function will be the primary outcome measure,.
This will be assessed using the Female Sexual Function
Index (FSFI). The FSFI comprises 19 questions of sexual
function in six independent areas consisting of desire
(two questions), arousal (four questions), lubrication
(four questions), orgasm (three questions), sexual satis-
faction (three questions) and pain from sex (three ques-
tions). Responses to the desire items are made on a six-
point Likert scale from 0 (never) to 5 (completely) with a
minimum score of 1 and a maximum score of 6. For
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other areas, responses are also made on a six-point
Likert scale from 0 (none) to 5 (completely) with a mini-
mum score of 0 and a maximum score of 6 [33]. The
validity of the Persian version of this scale was evaluated
and validated by Mohammadi et al. [34].
Secondary outcomes
The secondary outcome measure will be participants’
satisfaction with the intervention.
Baseline assessments
Evaluation of sexual function in postmenopausal women
will be performed among all three groups at the begin-
ning of the study and before the intervention.
Follow-up assessments
Sexual function of women among all three groups im-
mediately after the end of the intervention (duration of
the intervention will be 8 weeks), and one and 2 months
after the end of the intervention.
Safety issues
Overall, the total intake dose of vitamin D3 will be
32,000 units during the 8 weeks of the intervention. The
risk of poisoning with vitamin D is due to an overdose
of vitamin D3 is 50,000 units per month (according to
the Iran’s national guidelines) if administered over a long
period of time. Given that the overall dose used in the
proposed study is much lower than the level considered
by the country’s guidelines, the probability of poisoning
is low. In addition, to address concerns about the likeli-
hood of poisoning with vitamin D3, the participants
would be asked to withdraw taking supplemental vita-
min D3 during the study. In addition, all symptoms of
vitamin D3 poisoning will be taught to them and they
will be asked to discontinue the supplements and inform
the researcher if the signs of intoxication are detected.
Any side-effects will be reported at the end of study.
Data management and analysis
Data analysis and management will be performed using
the SPSS software version 25. After collecting data, data
entry will be performed on the dataset designed by ZS.
The data entry accuracy and screening will be performed
under the supervision of the ZA and MM. Initially, the
normal distribution of data is investigated using the
Kolmogorov-Smirnov test. In the case of normal distri-
bution of data, the comparison of the mean scores of
sexual function between the groups will be carried out
using the repeated measurements ANOVA test. If the
test is significant, a post-hoc test is used to determine
the difference between the groups. Comparison of
demographic and fertility characteristics of the women
in the groups will be performed using appropriate
statistical tests such as chi-square tests and one-way
ANOVAs. If the assumption of normality is violated,
transformation of data will be used. In most cases, trans-
formation will result in normally distributed data and
then parametric tests will be the main statistics
employed. If not, a mixed effect model or non-
parametric statistics will be used. A significance level of
p < .05 will be used for statistical analysis.
Discussion
Approximately one-third of postmenopausal women
have reported painful intercourse (dyspareunia), lack of
moisture, and lubrication [11]. Dyspareunia, vaginal dry-
ness, and lack of lubrication are due to vulvovaginal at-
rophy [9, 10]. Estrogen therapy is one of the therapeutic
methods for improving the symptoms of vaginal atrophy
and dyspareunia in postmenopausal women [14]. How-
ever, due to the potential risks of postmenopausal hor-
mone replacement therapy, systemic estrogen
replacement therapy may not always be acceptable for
women [8]. Concerns about the complications of estro-
gen therapy, including cardiovascular events, thrombo-
embolism, breast cancer, and endometrial hyperplasia
are among the most important reasons for the low ac-
ceptance of synthetic estrogen therapy and can lead
women to utilizing alternative treatments for relieving
menopausal symptoms [17].
Recent research has shown that vitamin D3 may also
be useful in preventing vaginal atrophy. Vitamin D3 may
play a role in regulating the growth and differentiation
of the vaginal epithelium [6]. The possible mechanism
for the effect of vitamin D on vagina is due to the pres-
ence of intracellular receptors of this vitamin in the basal
and parabasal cellular layer in the tissue of the vagina.
Because of these receptors in the vagina, vitamin D can
play an important role in regulating and increasing the
proliferation of epithelium cells in vagina [25, 26]. How-
ever, vitamin D receptors change during the menstrual
cycle, which means that by stopping ovarian activity, the
number of receptors are decreased [27]. Previous re-
search has shown that squamous cell differentiation
takes place in several steps, each of which is controlled
by specific genes [30, 31]. Results of a clinical trial study
on postmenopausal women showed that vitamin D vagi-
nal suppositories could experimentally (according to the
results of the participants’ Pap smear) improve dryness
and cell proliferation of the vaginal mucosa in postmen-
opausal women [24]. Also, results of a cross-sectional
study showed that the use of vitamin D supplements was
effective in the maturation of vaginal cells [22].
As previous studies have shown a promising effect of
vitamin D on vaginal cellularity and dryness, it might
also be useful in improving sexual function. To best of
the present authors’ knowledge, the proposed study is
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the first utilizing a randomized clinical trial design with
two concurrent control groups of placebo and no inter-
vention to examine the clinical effect of vaginal vitamin
D on sexual functioning among premenopausal women.
If vitamin D vaginal suppositories improve sexual func-
tion among premenopausal women with positive long-
term effects and minimum side effects, the suppositories
will be considered a safe complementary and alternative
choice for alleviating sexual dysfunction among this
group.
Trial status
The recruitment has begun and required permission has been acquired. To
date, 30 eligible participants have been invited to participate but the
intervention has not yet been started. The estimated date when intervention
will begin is August, 2019. The expected time for completing recruitment is
approximately February 2020.
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